Compare Novavax Inc (NVAX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Charles Schwab Corporation Common Stock — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Charles Schwab Corporation Common Stock trades at $100.2 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 137.2× Novavax Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SCHW | |
|---|---|---|
Market Cap | $1.30B | $178.33B |
Sector | Health | Financials |
52-Week High | $11.19 | $107.21 |
52-Week Low | $6.22 | $85.35 |
Enterprise Value | $800.50M | — |
Dividend Yield | — | 1.25% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
